A review of the potential therapeutic role of statins in the treatment of alzheimer's disease: Current research and opinion

Neuropsychiatric Disease and Treatment

Volumn 9, Issue 1, 2013, Pages 55-63

  Sánchez Ferro, Álvaro ^a,b,c,d   Benito León, Julián ^a,b,c   Mitchell, Alex J ^e   Bermejo Pareja, Félix ^a,b,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Animal models; Clinical trials; Cognitive function; Epidemiology; HMGCoA inhibitors; Prevention

Indexed keywords

26 HYDROXYCHOLESTEROL; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ATORVASTATIN; BETA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; CARDIOVASCULAR DISEASE; CLINICAL DEMENTIA RATING; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; REVIEW; RISK REDUCTION; SENILE PLAQUE; WECHSLER INTELLIGENCE SCALE;

EID: 84872065629     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S29105     Document Type: Review

References (107)

1. World Health Organization. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. Available from: http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdf. Accessed November 9, 2012.
2. Bermejo-Pareja F, Benito-Léon J, Vega S, Medrano MJ, Román GC; Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008;264(1-2):63-72.
3. Bermejo-Pareja F, Benito-Léon J, Vega S, et al. Consistency of clinical diagnosis of dementia in NEDICES: A population-based longitudinal study in Spain. J Geriatr Psychiatry Neurol. 2009;22(4):246-255.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
5. Villarejo A, Benito-Léon J, Trincado R, et al. Dementia-associated mortality at thirteen years in the NEDICES Cohort Study. J Alzheimers Dis. 2011;26(3):543-551.
6. Rivera J, Bermejo F, Franco M, Morales-González JM, Benito-Léon J. Understanding care of people with dementia in Spain: cohabitation arrangements, rotation and rejection to long term care institution. Int J Geriatr Psychiatry. 2009;24(2):142-148.
7. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343-354.
8. Grimm MO, Tschäpe JA, Grimm HS, Zinser EG, Hartmann T. Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. Acta Neurol Scand Suppl. 2006;185:S27-S32.
9. Lütjohann D. Cholesterol metabolism in the brain: importance of 24S-hydroxylation. Acta Neurol Scand Suppl. 2006;185:S33-S42.
10. Sparks DL, Hunsaker JC 3rd, Scheff S W, Kryscio RJ, Henson JL, Markes-bery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 1990;11(6):601-607.
11. Sparks DL, Scheff S W, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126(1):88-94.
12. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95(11): 6460-6464.
13. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(10): 5856-5861.
14. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110(5):597-603.
15. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271(8):4436-4440.
16. Rösler M, Anand R, Cicin-Sain A, et al. Effcacy and safety of rivastig-mine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633-638.
17. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercho-lesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology. 2003;61(2):199-205.
18. Reiss AB, Voloshyna I. Regulation of cerebral cholesterol metabolism in Alzheimer disease. J Investig Med. 2012;60(3):576-582.
19. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apo-lipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
20. Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging. 2011; 32(5):778-790.
21. Crean S, Ward A, Mercaldi CJ, et al. Apolipoprotein E ε4 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis. Dement Geriatr Cogn Disord. 2011;31(1):20-30.
22. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-1356.
23. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009;61(2):89-104.
24. Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7(11):850-859.
25. Björkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185: S43-S49.
26. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis. 2008;15(4):673-684.
27. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol. 2011;68(10):1239-1244.
28. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14-20.
29. Kivipelto M, Helkala EL, Laakso M P, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451.
30. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology. 1999;53(3):517-521.
31. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. 2004;61(5):705-714.
32. Mielke MM, Zandi P P, Sjögren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology. 2005;64(10):1689-1695.
33. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defned elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161-1168.
34. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 2000;20(10):2255-2260.
35. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med. 2003;163(9):1053-1057.
36. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2(8513):933-936.
37. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328(5):313-318.
38. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med. 1993;153(9):1065-1073.
39. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc. 1996;44(10):1147-1152.
40. Tsolaki M, Fountoulakis K, Chantzi E, Kazis A. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of a Greek population. Int Psychogeriatr. 1997;9(3):327-341.
41. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58(10):1640-1646.
42. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145.
43. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003;163(13):1524-1528.
44. Launer LJ, Ross G W, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55.
45. Bermejo-Pareja F, Benito-Léon J, Vega QS, et al. The NEDICES cohort of the elderly. Methodology and main neurological fndings. Rev Neurol. 2008;46(7):416-423. Spanish.
46. Vega S, Benito-Léon J, Bermejo-Pareja F, et al. Several factors infu-enced attrition in a population-based elderly cohort: neurological disorders in Central Spain Study. J Clin Epidemiol. 2010;63(2):215-222.
47. Morales JM, Bermejo F P, Benito-Léon J, et al; NEDICES Study Group. Methods and demographic findings of the baseline survey of the NEDICES cohort: a door-to-door survey of neurological disorders in three communities from Central Spain. Public Health. 2004;118(6):426-433.
48. Benito-Léon J, Louis ED, Rivera-Navarro J, Medrano MJ, Vega S, Bermejo-Pareja F. Low morale is associated with increased risk of mortality in the elderly: a population-based prospective study (NEDICES). Age Ageing. 2010;39(3):366-373.
49. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8(5):890-899.
50. Ramírez C, Sierra S, Tercero I, et al. ApoB100/LDLR-/- hypercholes-terolaemic mice as a model for mild cognitive impairment and neuronal damage. PLoS One. 2010;6(7):e22712.
51. Mizuno T, Nakata M, Naiki H, et al. Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem. 1999;274(21):15110-15114.
52. Michikawa M, Yanagisawa K. Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death. J Neurochem. 1999;72(6):2278-2285.
53. Sparks DL. Alzheimer disease: statins in the treatment of Alzheimer disease. Nat Rev Neurol. 2011;7(12):662-663.
54. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;15(2): CD003160.
55. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;4(8):CD007514.
56. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-1443.
57. Burgos J, Benavides J, Douillet P, Velasco J, Valdivieso F. How statins could be evaluated successfully in clinical trials for Alzheimer's disease? Am J Alzheimer Dis Other Demen. 2012;27(3):151-153.
58. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
59. Crisby M. The role of pleiotropic effects of statins in dementia. Acta Neurol Scand Suppl. 2006;185:S115-S118.
60. Butterfeld DA, Barone E, Mancuso C. Cholesterol-independent neu-roprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res. 2011;64(3):180-186.
61. Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophi-licity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23(2): 307-318.
62. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol. 2011;68(11):1385-1392.
63. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-1631.
64. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer G P. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57(7):M414-M418.
65. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr G P, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002; 50(11):1852-1856.
66. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378-384.
67. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiolog y. 2004;23(1-2):94-98.
68. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047-1051.
69. Dufouil C, Richard F, Fiévet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurolog y. 2005;64(9):1531-1538.
70. Cramer C, Haan MN, Galea S, Langa KM, Kalbfeisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008;71(5):344-350.
71. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-17.
72. Zandi P P, Sparks DL, Khachaturian AS, et al; Cache County Study Investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62(2):217-224.
73. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795-1802.
74. Benito-Léon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1):95-102.
75. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85-90.
76. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
77. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37(3):231-236.
78. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34(10):989-996.
79. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39(3):333-336.
80. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18(4):209-214.
81. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72(9):805-812.
82. Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials. 2004;25(2):178-202.
83. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of ator-vastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy. 2007;27(2):183-190.
84. Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the infuence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis. 2010;7(1-3):183-186.
85. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008;5(4):416-421.
86. Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fuid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008;13(2):187-197.
87. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmaco-logic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc. 1997;45(1):8-14.
88. Muldoon M F, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000; 108(7):538-546.
89. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11):823-829.
90. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250-1251.
91. Parale G P, Baheti NN, Kulkarni PM, Panchal N V. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4):259-265.
92. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24(8):1335-1341.
93. Simons M, Schwärzler F, Lütjohann D, et al. Treatment with sim-vastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52(3):346-350.
94. Feldman HH, Doody RS, Kivipelto M, et al; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-964.
95. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556-563.
96. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:S3-S7.
97. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62(5):753-757.
98. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59(2):223-227.
99. Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ. 2008;179(7): 645-652.
100. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009; 29(7):800-811.
101. Agostini J V, Tinetti ME, Han L, McAvay G, Foody JM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55(3):420-425.
102. Glasser S P, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol. 2010;33(5):280-288.
103. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549-557.
104. Jukema J W, Cannon C P, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875-881.
105. Institute for the Study of Aging (ISOA). Lipitor as a treatment for Alzheimer's disease. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2001 [updated November 8, 2006]. Available from: http://clinicaltrials.gov/ct2/show/ NCT00024531. NLM identifer: NCT00024531. Accessed September 30, 2012.
106. Pfzer. To evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in AD patients. In: Clinical Trials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2005 [updated July 9, 2008]. Available from: http://clinicaltrials.gov/ ct2/show/NCT00151502. NLM identifer: NCT00151502. Accessed September 30, 2012.
107. National Institute on Aging (NIA). Cholesterol lowering agent to slow progression (CLASP) of Alzheimer's disease study. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2003 [updated July 24, 2009]. Available from: http:// clinicaltrials.nlm.nih.gov/ct2/show/NCT00053599. NLM identifier: NCT00053599. Accessed September 30, 2012.